Oncology Tests

by Monogram Biosciences is now available.

 

 

  • HERmark® offers a novel HER-2 testing alternative to identify candidates for HER2-targeted therapy
  • HERmark results are accurate and reproducible
  • HERmark is performed at a CAP-accredited central lab
  • HERmark is covered by Medicare

HERmark Breast Cancer Assay precisely quantifies HER-2 total protein levels in formalin-fixed parrafin-embedded (FFPE) tissue. The assay performance characteristics are validated according to CLIA standards. HERmark results provide health care professionals with additional information for managing breast cancer patients.

VeraTag®

Monogram offers proprietary VeraTag technology for oncology and is a fully quantitative HER-2 protein test. VeraTag technology provides pharmaceutical partners and academic collaborators with sensitive and quantitative measurements of cell-surface receptors and activated proteins and complexes in cancer cell lines, xenografts, and multiple solid tumor types.

  • Measures total protein levels, phosphorylated proteins, homo- or heterodimers, and protein-protein complexes
  • Accurate quantification by capillary electrophoresis (CE)
  • Enhanced sensitivity and dynamic range compared to standard protein biomarker technologies
  • For use in cell lines, xenografts, fresh-frozen, and FFPE breast, head/neck, lung, gastric, colorectal, ovarian, and other solid tumors.
  • Cell or tumor lysate and fresh-frozen or FFPE platforms

Click here to learn more about VeraTag.